Join the Asthma group to help and get support from people like you.
Asthma News (Page 7)
Related terms: Bronchial Asthma, Exercise-induced asthma, Wheezing
Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved ArmonAir...
Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AirDuo...
Symbicort Approved for the Treatment of Asthma in Patients 6 to 12 Years of Age
26 January 2017 – AstraZeneca today announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of pediatric exclusivity for Symbicort (budesonide/formoterol)...
FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
South San Francisco, CA – July 7, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair...
Teva Announces FDA Approval of ProAir RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11
JERUSALEM--(BUSINESS WIRE)--Apr. 29, 2016-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick...
FDA Approves Cinqair (reslizumab) to Treat Severe Asthma
March 23, 2016 – The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18...
FDA Approves Nucala (mepolizumab) to Treat Severe Asthma
November 4, 2015 - The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and...
FDA Approves Spiriva Respimat (tiotropium) for Maintenance Treatment of Asthma in Adults and Adolescents
RIDGEFIELD, Conn., September 16, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat for the long-term, o...
FDA Approves Breo Ellipta (fluticasone furoate/vilanterol) for Asthma
London, UK, and South San Francisco, CA, USA, 30 April 2015 – GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has a...
Teva Announces FDA Approval of ProAir RespiClick
JERUSALEM--(BUSINESS WIRE)--Apr. 1, 2015-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick (albuterol...
FDA Medwatch Alert: Over-the-Counter Asthma Products Labeled as Homeopathic: FDA Statement - Consumer Warning About Potential Health Risks
ISSUE: FDA is warning consumers not to rely on asthma products labeled as homeopathic that are sold over-the-counter (OTC). These products have not been evaluated by the FDA for safety and e...
FDA Medwatch Alert: Xolair (omalizumab): Drug Safety Communication - Slightly Elevated Risk of Cardiovascular and Cerebrovascular Serious Adverse Events
ISSUE: An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug...
FDA Approves Arnuity Ellipta (fluticasone furoate) for the Treatment of Asthma
20 August 2014 – GlaxoSmithKline plc today announced that the Food and Drug Administration has approved Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid...
FDA Medwatch Alert: Albuterol Sulfate Inhalation Solution, 0.083 percent (Nephron Pharmaceuticals): Recall - Aseptic Processing Simulation Results
ISSUE: Nephron Pharmaceuticals initiated a voluntary recall, at the retail level, of ten lots of product due to results from an internal monitoring process. NPC performs aseptic process simulation...
Horizon Pharma Announces FDA Approval of Rayos (prednisone) Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications
DEERFIELD, Ill., July 26, 2012 /PRNewswire/ – Horizon Pharma, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Rayos (prednisone) delayed-release tablets (1 mg, 2...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Asthma - Maintenance, Asthma - Acute
Related drug support groups
prednisone, methylprednisolone, albuterol, caffeine, triamcinolone, Medrol, Xolair, Trelegy Ellipta, dexamethasone, fluticasone, montelukast, budesonide, omalizumab